PCSA Stock Analysis: Buy, Sell, or Hold?
PCSA - Processa Pharmaceuticals, Inc. Common
$1.61
-0.01 (-0.62%)
▼
5d:
-12.5%
30d:
-23.33%
90d:
-23.33%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When PCSA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PCSA is down 12.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PCSA is down 12.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PCSA is currently trading at $1.61, which is considered oversold relative to its 30-day fair value range of $1.78 to $2.09.
Technical Outlook: Technically, PCSA is in a downtrend. The price is currently testing key support at $1.57. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PCSA scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.00 (+1452.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PCSA is in a downtrend. The price is currently testing key support at $1.57. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PCSA scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $25.00 (+1452.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.78 -
$2.09
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1452.8% below Wall St target ($25.00)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.78 -
$2.09
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.57
Resistance Level
$2.02
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.43
Wall Street Target
$25.00
(+1452.8%)
Share & Embed Analysis
Last updated: October 03, 2026 11:51 PM ET
Data refreshes hourly during market hours. Next update: 12:51 AM
Data refreshes hourly during market hours. Next update: 12:51 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCSA showing a specific setup today?
Insider Activity (6 Months)
5
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
David Young
BUY
1545 shares
2026-04-15
George K Ng
BUY
1843 shares
2026-04-15
Russell Skibsted
BUY
1984 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 66 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 60 BUY |
